Objective To evaluate the application effect of modified digestive tract reconstruction combined with tegafur oral chemotherapy in the treatment of patients with gastric cancer. Methods The clinical data of 121 patients with gastric cancer treated in the hospital were collected between January 2018 and March 2021, and were divided into observation group(modified digestive tract reconstruction and postoperative conventional oxaliplatin combined with tegafur chemotherapy, 61 cases) and control group(traditional digestive tract reconstruction and postoperative conventional oxaliplatin combined with tegafur chemotherapy, 60 cases) for retrospective study according to different treatment methods. The clinical efficacy and changes in blood indicators such as fibrinogen(FIB) and prealbumin(PA) before treatment and after 2 months of treatment were compared between the two groups of patients. The changes in tumor markers ［carcinoembryonic antigen(CEA), carbohydrate antigen 19-9(CA19-9), carbohydrate antigen 72-4(CA72-4), pepsin I(PGI)］ were analyzed in the two groups of patients. The occurrence of postoperative complications(diarrhea, anastomotic leakage, reflux esophagitis, dumping syndrome and retention syndrome) and Nutrition Assessment Index(NAI) and Gastrointestinal Symptom Rating Scale(GSRS) were compared. Results In terms of clinical efficacy, the clinical effective rate of 95.09% in observation group was higher than 81.46% in control group(P＜0.05), and the efficacy grading of observation group was better than that of control group(P＜0.05). As for blood indicators, the level of Fib after treatment of observation group was lower than that of control group while the level of PA was higher than that of control group(P＜0.05). After treatment, there were no significant differences in the tumor markers between the two groups(P＞0.05), but the tumor markers in the two groups were improved compared with those before treatment(P＜0.05). The incidence rate of postoperative complications of 6.56% in observation group was lower than 21.67% in control group(P＜0.05).(5) After treatment, the scores of quality of life of NAI and GSRS of observation group were higher than those of control group(P＜0.05). Conclusion Modified digestive tract reconstruction combined with tegafur oral chemotherapy has a more significant efficacy in the treatment of patients with gastric cancer, and it can promote the disease recovery, improve the prognosis, and enhance the quality of life of patients.